These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9356581)

  • 41. Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.
    Pozo P; Alcántara AG
    J Psychiatry Neurosci; 1998 Nov; 23(5):309-10. PubMed ID: 9846037
    [No Abstract]   [Full Text] [Related]  

  • 42. Olanzapine-induced agranulocytosis.
    Naumann R; Felber W; Heilemann H; Reuster T
    Lancet; 1999 Aug; 354(9178):566-7. PubMed ID: 10470705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olanzapine, sertindole and schizophrenia.
    Drug Ther Bull; 1997 Nov; 35(11):81-3. PubMed ID: 9464002
    [No Abstract]   [Full Text] [Related]  

  • 44. British experience with high-dose olanzapine for treatment-refractory schizophrenia.
    Mountjoy CQ; Baldacchino AM; Stubbs JH
    Am J Psychiatry; 1999 Jan; 156(1):158-9. PubMed ID: 9892320
    [No Abstract]   [Full Text] [Related]  

  • 45. Some aspects of psychodynamic response to novel atypical antipsychotics.
    Murawiec S; Taflińska D; Tafliński T
    Harv Rev Psychiatry; 1999; 7(4):241-2. PubMed ID: 10579106
    [No Abstract]   [Full Text] [Related]  

  • 46. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A possible association between high normal and high dose olanzapine and prolongation of the PR interval.
    Kosky N
    J Psychopharmacol; 2002 Jun; 16(2):181-2. PubMed ID: 12095078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefits of olanzapine as first-line schizophrenia therapy.
    Cohen LJ
    Am J Health Syst Pharm; 1999 Aug; 56(15):1559-60, 1563-4. PubMed ID: 10478999
    [No Abstract]   [Full Text] [Related]  

  • 49. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.
    Llorca PM; Vaiva G; Lancon C
    Can J Psychiatry; 2001 Feb; 46(1):87-8. PubMed ID: 11221497
    [No Abstract]   [Full Text] [Related]  

  • 50. [Zyprexa (olanzapine)--new possibilities in the treatment of schizophrenia].
    Litvintsev SV; Reznik AM; Arbuzov AL; Kutushev OT; Shcherbakov DV
    Voen Med Zh; 2002 Sep; 323(9):46-50. PubMed ID: 12449756
    [No Abstract]   [Full Text] [Related]  

  • 51. [Use of novel agents in the treatment of schizophrenia and a look to the future].
    Keks NA
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):97-101. PubMed ID: 9800201
    [No Abstract]   [Full Text] [Related]  

  • 52. [Olanzapine. A new antipsychotic agent].
    Bredkjoer SR; Gerlach J
    Ugeskr Laeger; 1997 Nov; 159(48):7160-4. PubMed ID: 9417725
    [No Abstract]   [Full Text] [Related]  

  • 53. Hypersalivation coincident with olanzapine treatment.
    Perkins DO; McClure RK
    Am J Psychiatry; 1998 Jul; 155(7):993-4. PubMed ID: 9659875
    [No Abstract]   [Full Text] [Related]  

  • 54. Olanzapine-induced somnambulism.
    Kolivakis TT; Margolese HC; Beauclair L; Chouinard G
    Am J Psychiatry; 2001 Jul; 158(7):1158. PubMed ID: 11431244
    [No Abstract]   [Full Text] [Related]  

  • 55. Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.
    Gray R
    Ment Health Care; 1998 Feb; 1(6):193-4. PubMed ID: 9791411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurologic soft signs and olanzapine treatment in chronic schizophrenia.
    Sevincok L; Topaloglu B; Kiyilioglu N
    J Clin Psychopharmacol; 2004 Oct; 24(5):571-2. PubMed ID: 15349026
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.
    Di Lorenzo R; Tondelli G; Genedani S
    Int J Neuropsychopharmacol; 2001 Jun; 4(2):135-7. PubMed ID: 11466163
    [No Abstract]   [Full Text] [Related]  

  • 58. Marked reduction of tardive dyskinesia with olanzapine.
    Littrell KH; Johnson CG; Littrell S; Peabody CD
    Arch Gen Psychiatry; 1998 Mar; 55(3):279-80. PubMed ID: 9510225
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of preexisting diabetes with olanzapine.
    Littrell KH; Petty RG; Peabody CD; Hilligoss NM; Johnson CG
    J Clin Psychiatry; 2001 Sep; 62(9):733-4. PubMed ID: 11681771
    [No Abstract]   [Full Text] [Related]  

  • 60. Olanzapine-induced obsessive-compulsive disorder.
    Mottard JP; de la Sablonnière JF
    Am J Psychiatry; 1999 May; 156(5):799-800. PubMed ID: 10327925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.